

Testosterone:

Cavender R, Fairall M. Subcutaneous Testosterone Pellet Implant (Testopel®) Therapy for Men with Testosterone Deficiency Syndrome: A Single-Site Retrospective Safety Analysis. *Journal Of Sexual Medicine* [serial online]. November 2009;6(11):3177-3192. Available from: Academic Search Complete, Ipswich, MA. Accessed February 4, 2014.

Glaser R, York A, Dimitrakakis C. Beneficial effects of testosterone therapy in women measured by the validated Menopause Rating Scale (MRS). *Maturitas* [serial online]. April 2011;68(4):355-361. Available from: MEDLINE, Ipswich, MA. Accessed February 4, 2014.

Gray K, Derosa A. Subcutaneous pellet testosterone replacement therapy: the "first steps" in treating men with spinal cord injuries. *JAOA: Journal Of The American Osteopathic Association* [serial online]. December 2013;113(12):921-925. Available from: CINAHL Plus with Full Text, Ipswich, MA. Accessed February 4, 2014.

Hameed A, Brothwood T, Bouloux P. Delivery of testosterone replacement therapy. *Current Opinion In Investigational Drugs (London, England: 2000)* [serial online]. October 2003;4(10):1213-1219. Available from: MEDLINE, Ipswich, MA. Accessed February 4, 2014.

Kaminetsky J, Moclair B, Hernani M, Sand M. A Phase IV Prospective Evaluation of the Safety and Efficacy of Extended Release Testosterone Pellets for the Treatment of Male Hypogonadism. *Journal Of Sexual Medicine* [serial online]. April 2011;8(4):1186-1196. Available from: Academic Search Complete, Ipswich, MA. Accessed February 4, 2014.

Kelleher, Turner, Howe, Conway, Handelsman, Handelsman. Extrusion of testosterone pellets: a randomized controlled clinical study. *Clinical Endocrinology* [serial online]. October 1999;51(4):469-471. Available from: Academic Search Complete, Ipswich, MA. Accessed February 4, 2014.

Kelleher S, Conway A, Handelsman D. Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants. *Clinical Endocrinology* [serial online]. October 2001;55(4):531-536. Available from: MEDLINE, Ipswich, MA. Accessed February 4, 2014.

Kelleher S, Howe C, Conway A, Handelsman D. Testosterone release rate and duration of action of testosterone pellet implants. *Clinical Endocrinology* [serial online]. April 2004;60(4):420-428. Available from: MEDLINE, Ipswich, MA. Accessed February 4, 2014.

Mechlin C, Frankel J, McCullough A. Coadministration of Anastrozole Sustains Therapeutic Testosterone Levels in Hypogonadal Men Undergoing Testosterone Pellet Insertion. *Journal Of Sexual Medicine* [serial online]. January 2014;11(1):254-261. Available from: Academic Search Complete, Ipswich, MA. Accessed February 4, 2014.

Moskovic D, Freundlich R, Yazdani P, Lipshultz L, Khera M. Subcutaneous implantable testosterone pellets overcome noncompliance in adolescents with Klinefelter syndrome. *Journal Of Andrology* [serial online]. July 2012;33(4):570-573. Available from: MEDLINE, Ipswich, MA. Accessed February 4, 2014.

Pastuszak A, Mittakanti H, Liu J, Gomez L, Lipshultz L, Khera M. Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets. *Journal Of Andrology* [serial online]. September 2012;33(5):927-937. Available from: MEDLINE, Ipswich, MA. Accessed February 4, 2014.

Sahores A, Luque G, Lamb C, et al. Novel, Low Cost, Highly Effective, Handmade Steroid Pellets for Experimental Studies. *Plos ONE* [serial online]. May 2013;8(5):1-9. Available from: Academic Search Complete, Ipswich, MA. Accessed February 4, 2014.

Smith R, Khanna A, Lipshultz L, et al. Factors Influencing Patient Decisions to Initiate and Discontinue Subcutaneous Testosterone Pellets (Testopel) for Treatment of Hypogonadism. *Journal Of Sexual Medicine* [serial online]. September 2013;10(9):2326-2333. Available from: Academic Search Complete, Ipswich, MA. Accessed February 4, 2014.

Prostate:

Feneley M, Carruthers M. Is testosterone treatment good for the prostate? Study of safety during long-term treatment. *The Journal Of Sexual Medicine* [serial online]. August 2012;9(8):2138-2149. Available from: MEDLINE, Ipswich, MA. Accessed February 4, 2014.

Gearhart J, Witherington R, Coleman C. Subcutaneous estradiol pellet implantation in management of advanced prostatic carcinoma. *Urology* [serial online]. January 1981;17(1):44-48. Available from: MEDLINE, Ipswich, MA. Accessed February 4, 2014.

Menopause:

Nachtigall L, Nachtigall M. Hormone replacement therapy. *Current Opinion In Obstetrics & Gynecology* [serial online]. December 1992;4(6):907-913. Available from: MEDLINE, Ipswich, MA. Accessed February 4, 2014.

Tzingounis, V., Perdikaris, A., Lioutas, G., & Dimopoulos, D. (1993). Subcutaneous hormone replacement therapy. *European Journal Of Obstetrics, Gynecology, And Reproductive Biology*, 49(1-2), 64-66.

Breast Cancer:

Glaser R, Dimitrakakis C. Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: A prospective, observational study. *Maturitas* [serial online]. December 2013;76(4):342-349. Available from: Academic Search Complete, Ipswich, MA. Accessed February 4, 2014

Colon Cancer:

Armstrong C, Billimek A, Allred K, Sturino J, Weeks B, Allred C. A novel shift in estrogen receptor expression occurs as estradiol suppresses inflammation-associated colon tumor formation. *Endocrine-Related Cancer* [serial online]. August 2013;20(4):515-525. Available from: Academic Search Complete, Ipswich, MA. Accessed February 4, 2014.

Cardiovascular Risk:

Flues K, Paulini J, De Angelis K, et al. Exercise training associated with estrogen therapy induced cardiovascular benefits after ovarian hormones deprivation. *Maturitas* [serial online]. March 2010;65(3):267-271. Available from: Academic Search Complete, Ipswich, MA. Accessed February 4, 2014.